Last Patient Enrolled in Pivotal Phase 3 Parkinson’s Disease Trial, Cynapsus Therapeutics Says
News
Cynapsus Therapeutics has enrolled the final patient in its pivotal Phase 3 clinical study investigating the clinical effects of APL-130277, a fast-acting sublingual thin film for the treatment of debilitating OFF states in Parkinson’s ... Read more